Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Buyback Yield % : 0.00 (As of May. 28, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Eucrates Biomedical Acquisition's current buyback yield was 0.00%.

Eucrates Biomedical Acquisition Buyback Yield % Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Buyback Yield % Chart

Eucrates Biomedical Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

Buyback Yield %

Eucrates Biomedical Acquisition Quarterly Data
	Aug20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Buyback Yield %	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Eucrates Biomedical Acquisition's Buyback Yield %

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eucrates Biomedical Acquisition's Buyback Yield % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's Buyback Yield % falls into.

Eucrates Biomedical Acquisition Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Eucrates Biomedical Acquisition's Buyback Yield for the fiscal year that ended in Dec. 2022 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (-93.191	+	0)	/
	=	N/A%

Eucrates Biomedical Acquisition's annualized Buyback Yield for the quarter that ended in Dec. 2022 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/
	=	N/A%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Dec. 2022) data.

Eucrates Biomedical Acquisition Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

250 West 55th Street, Suite 13D, New York, NY, USA, 10019

Website

Eucrates Biomedical Acquisition Corp is a blank check company.

Executives

Stelios Papadopoulos	director, 10 percent owner	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell	director	270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro	director	2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena	director, 10 percent owner, officer: Chief Executive Officer	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal	officer: Vice President	250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova	officer: Chief Financial Officer	250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe	officer: Senior Vice President	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis	director, officer: President, COO	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal	director	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines

From GuruFocus

Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering

By PRNewswire PRNewswire • 10-28-2020

Eucrates Biomedical Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 06-01-2021

Eucrates Biomedical Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 04-11-2023